Deputy Director, Precision Cancer Therapies (Phase I) Research Program
Dr. Johnson graduated medical school and completed internal medicine residency at Louisiana State University School of Medicine in New Orleans, where he also served as chief resident. Completed his fellowship in hematology and medical oncology at University of Texas MD Anderson Cancer Center in Houston, TX. He is currently a medical oncologist and deputy director of the precision cancer therapies program at the Gayle and Tom Benson Cancer Center at Ochsner Medical Center.Dr. Johnson specializes in treating patients with advanced melanoma with specific research interests in strategies to overcome immunotherapy resistance and prevent immunotherapy related toxicities. Dr. Johnson is a clinical investigator focusing on designing and implementing clinical trials intended to optimize the safety and efficacy of immune checkpoint inhibitors.
Johnson DH, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, Tetzlaff MT, Hwu P., Curry JL, and Diab A. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. Cancer Immunology Research 2019. 7(6), pp.860-865
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D.H., Zobniw, C.M., Lin, H., Wong, M.K., Abdelrahim, M., Gaber, A.O., Suarez-Almazor, M.E. and Diab, A., 2019. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. Journal for immunotherapy of cancer, 7(1), p.106.
Curry, J.L., Reuben, A., Szczepaniak‐Sloane, R., Jing, N., Milton, D.R., Lee, C.H., Hudgens, C., George, S., Torres‐Cabala, C., Johnson, D. and Subramanya, S., 2019. Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. Journal of cutaneous pathology. 2019; 1– 10.
Johnson DH, Zobinw C, Trinh VA, Ma J, Bassett R, et al. Infliximab associated with faster symptom resolution compared to corticosteroids alone for management of immune mediated enterocolitis. Journal for ImmunoTherapy of Cancer 2018 6:103.
Chen, W.S., Tetzlaff, M.T., Diwan, H., Jahan‐Tigh, R., Diab, A., Nelson, K., Glitza, I.C., Kaunitz, G.J., Johnson, D., Torres‐Cabala, C. and Pacha, O., 2018. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus‐like to Grover‐like lesions. Journal of Cutaneous Pathology.
Wang, Y., Abu-Sbeih, H., Mao, E., Ali, N., Qiao, W., Trinh, V.A., Zobniw, C., Johnson, D.H., Samdani, R., Lum, P. and Shuttlesworth, G., 2018. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. Inflammatory Bowel Diseases.
Kim, S.T., Tayar, J., Suarez-Almazor, M., Garcia, S., Hwu, P., Johnson, D.H., Uemura, M. and Diab, A. 2017. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the rheumatic diseases, 76(12), pp.2061-2064.